UNSPSC 51283723: Cefprozil anhydrous

This classification denotes a cephalosporin antibiotic with the molecular formula C18H19N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1M698F4H4E, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-(1-propenyl)-, (6r-(6.alpha.,7.beta.(r*)))-, but more generally known as cefprozil anhydrous, which bears US NIH Compound Identifier 5281006.

European Medicines Agency schedules cefprozil anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07415MIG. Most nations, for tariff purposes, schedule cefprozil anhydrous under HS 29419000. SMILES:. Cefprozil anhydrous bears US NLM identifiers UMLS ID C2699143 and NCI Concept Code C79994.

UNSPSC 51283723 Cefprozil anhydrous, a Commodity code, shows a mismatch between its nominal scope and recent state and local solicitation activity. The code targets a specific antibiotic pharmaceutical product, but the recent opportunities tagged to it—naloxone procurement, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing—do not align with cefprozil anhydrous acquisition. The code appears to see little relevant recent activity tied to its actual product specification.

The solicitations captured under this code span multiple issuing-body types and geographies but reflect procurement of broader pharmaceutical categories rather than cefprozil specifically. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems; the City of Tampa issued an IFB (26P00145, due March 13, 2026) for medical and first aid supplies estimated at $700,000 for the Fire Department Rescue Division with a 5% bid discount for certified Small Local Business Enterprises; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon; and the Texas Health and Human Services Commission issued an RFI (HHS0017013, dated April 3, 2026) to explore direct-to-manufacturer prescription programs. The geographic spread includes Florida, Texas, Minnesota, and Oregon, though the activities do not target cefprozil anhydrous as a line item.